Guías Clínicas
Guías tam izaje, d iagn óstico y tratam ien to de l hepa toca rcinoma - Sociedad Chilena de Gastroenterología
Hepatocellular Carcinoma. N Engl J
Med. 2018;379:54-63.
259.- Zhu AX, Baron AD, Malfertheiner P,
Kudo M, Kawazoe S, Pezet D, et al.
Ramucirumab as Second-Line
Treatment in Patients With
Advanced Hepatocellular Carcinoma:
Analysis of REACH Trial Results
by Child-Pugh Score. JAMA Oncol.
2017;3:235-43.
260.- Zhu AX, Kang Y-K, Yen C-J, Finn
RS, Galle PR, Llovet JM, et al.
REACH-2: A Randomized, Doubleblind,
106
Placebo-controlled Phase 3 Study
of Ramucirumab Versus Placebo as
Second-line Treatment in Patients With
Advanced Hepatocellular Carcinoma
(CHC) and Elevated Baseline Alphafetoprotein
(AFP) Following First-line
Sorafe. J Clin Oncol. 2018;36:4003.
261.- Llovet JM, Kudo M, Finn R,
Galle PR, Blanc J-F, Okusaka T,
et al. Ramucirumab As Second-
Line Treatment in Patients with
Hepatocellular Carcinoma (CHC) and
Elevated Alpha-Fetoprotein (AFP)
Following Sorafenib: Pooled Results
from Two Global Phase 3 Studies
(REACH-2 and REACH). Hepatology.
2018;68:166A.
262.- El-khoueiry AB, Sangro B, Yau T,
Crocenzi TS, Kudo M, Hsu C, et al.
Nivolumab in Patients with Advanced
Hepatocellular Carcinoma (CheckMate
040): An Open-label, Non-comparative,
Phase 1/2 Dose Escalation and
Expansion Trial. Lancet. 2017;389:2492-
502.
263.- Zhu AX, Finn RS, Edeline J, Cattan
S, Ogasawara S, Palmer D, et al.
Pembrolizumab in Patients with
Advanced Hepatocellular Carcinoma
Previously Treated with Sorafenib
(KEYNOTE-224): A Non-randomised,
Open-label Phase 2 Trial. Lancet Oncol.
2018;19:940-52.
264.- Nishie A, Goshima S, Haradome H,
Matsuda M, Motosugi U, Saitoh S, et
al. Cost-effectiveness of EOB-MRI for
Hepatocellular Carcinoma in Japan. Clin
Ther. 2017;39:738-50.e4.
265.- Zangneh H, Wong W, Sander B, Bell
C, Mumtaz K, Kowgier M, et al.
Cost-effectiveness of Hepatocellular
Carcinoma Surveillance After a
Sustained Virologic Response to Therapy
in Patients With HCV Infection and
Advanced Fibrosis. Clin Gastroenterol
Hepatol. 2018;S1542-3565:31394-6.
266.- Cadier B, Bulsei J, Nahon P, Seror
O, Laurent A, Rosa I, et al. Early
Detection and Curative Treatment of
Hepatocellular Carcinoma: A Cost-
Effectiveness Analysis in France and in
the United States Benjamin. Hepatology.
2017;65:1237-48.
Gastroenterol. latinoam 2019; Vol 30, Nº 2: 64-106